Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT ORLOWSKI and BEHRANG AMINI.
Connection Strength
1.132
-
Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 2020 05; 105(5):e242-e245.
Score: 0.176
-
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019 08 13; 3(15):2400-2408.
Score: 0.176
-
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018 Dec; 5(12):e628-e640.
Score: 0.167
-
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.
Score: 0.149
-
Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 May 01; 119(1):193-199.
Score: 0.059
-
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J. 2021 02 08; 11(2):17.
Score: 0.049
-
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol. 2021 02; 192(4):e115-e120.
Score: 0.049
-
SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma. 2020 11; 61(11):2763-2766.
Score: 0.047
-
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):e221-e238.
Score: 0.045
-
New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica. 2020 07; 105(7):e355-e357.
Score: 0.045
-
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019 05 29; 11(494).
Score: 0.043
-
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):560-569.
Score: 0.043
-
Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated? Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):e465-e469.
Score: 0.043
-
Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr?m's macroglobulinemia. Leuk Lymphoma. 2019 04; 60(4):964-970.
Score: 0.041